cerebral small vessel disease
Conditions
Interventions
control:none
cerebral small vessel disease:none
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: CSVD Group 1. Aged 50-80 years, no gender restriction; 2. The main inclusion criterion is moderate to severe white matter lesions on imaging (Fazekas grade 2 or 3), which may be accompanied by lacunes, microbleeds, EPVS, and brain atrophy. The imaging diagnostic criteria are based on the 2013 STRIVE standards for neuroimaging [Lancet Neurol 2013;12:822-838]; 3. The patient or their close relatives can understand and voluntarily sign the informed consent form and cooperate with related examinations. Control Group 1. No lacunes, microbleeds, or EPVS on baseline imaging; may include mild white matter lesions recommended as vascular in origin (Fazekas grade 0 or 1) and age-appropriate brain atrophy; 2. The patient or their close relatives can understand and voluntarily sign the informed consent form and cooperate with related examinations.
Exclusion criteria
Exclusion criteria: CSVD Group 1. Territorial infarction or subcortical infarction (>2cm); 2. Thromboembolic infarction; 3. Presence of intracranial or extracranial vascular lesions (stenosis >50%); 4. History of clearly symptomatic stroke; 5. Vascular disease caused by other reasons (e.g., genetically confirmed or suspected hereditary vascular disease based on medical and family history; probable or possible CAA diagnosed according to Boston criteria; immune-related CSVD caused by autoimmune diseases, etc.); 6. Brain parenchymal damage caused by other reasons, such as normal pressure hydrocephalus, multiple sclerosis, toxic-metabolic diseases, etc.; 7. Patients with a clear diagnosis of arrhythmia, including atrial fibrillation, frequent atrial premature beats, and ventricular premature beats; 8. Patients with a clear diagnosis of severe sleep disorders who have received medication treatment; 9. Patients with severe anxiety and depression; 10. Patients with severe medical conditions, including liver or kidney dysfunction, organ failure, respiratory failure, etc.; 11. Patients allergic to contrast agents for MRI or who have had severe allergic reactions; 12. Patients with contraindications to MRI and those with claustrophobia. Control Group 1. Patients with a clearly diagnosed history of cerebrovascular disease, Parkinson’s disease, myasthenia gravis, or other neurological disorders; 2. Patients with a clear diagnosis of arrhythmia, including atrial fibrillation, frequent atrial premature beats, and ventricular premature beats; 3. Patients with a clear diagnosis of severe sleep disorders who have received medication treatment; 4. Patients with severe anxiety and depression; 5. Patients with severe medical conditions, including liver or kidney dysfunction, heart failure, respiratory failure, etc.; 6. Patients allergic to contrast agents for MRI or who have had severe allergic reactions; 7. Patients with contraindications to MRI and those with claustrophobia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glymphatic function; | — |
Countries
China
Contacts
Public ContactMiaoyi Zhang
Huashan Hospital, Fudan University
Outcome results
None listed